Icos Corporation

Chiron Corporation

Lawrence S Cousens

Patrick W Gray

Larry W Tjoelker

Cheryl L Wilder

Hai Le Trong

Christine D Eberhardt

Patricia A Tekamp-Olson

Pablo D Valenzuela

Anthony J Brake

Mickey S Urdea

Jeffrey R Shuster

James P Merryweather

Graeme Ian Bell

The present invention provides purified and isolated polynucleotide sequences encoding human plasma platelet-activating factor acetylhydrolase. Also provided are materials and methods for the recombinant production of platelet-activating factor acetylhydrolase products which are expected to be useful in regulating pathological inflammatory events.

Platelet-activating factor acetylhydrolase

The present invention provides purified and isolated polynucleotide sequences encoding human plasma platelet-activating factor acetylhydrolase. Also provided are materials and methods for the recombinant production of platelet-activating factor acetylhydrolase products which are expected to be useful in regulating pathological inflammatory events. Specifically disclosed are methods for the treatment of reperfusion injury using platelet-activating factor acetylhydrolase products.

Platelet-activating factor acetylhydrolase (PAF-AH) therapeutic uses

Protein aggregates obtained by a process comprising culturing a host cell that expresses a desired protein in a medium comprising an effective amount of Cu.sup.++ and wherein the desired protein forms inclusion bodies in the host cell.

Enhanced purification and expression of insoluble recombinant proteins

Antibodies specific for platelet-activating factor acetylhydrolase

Methods of detecting platelet-activating factor acetylhydrolase using

The present invention provides purified and isolated polynucleotide sequences encoding human plasma platelet-activating factor acetylhydrolase. Also provided are materials and methods for the recombinant production of platelet-activating factor acetylhydrolase products which are expected to be useful in regulating pathological inflammatory events. Furthermore provided are therapeutic and diagnostic methods using such polynucleotide sequences and platelet-activating factor acethylhydrolase products.

Methods of detecting lesions in the platelet-activating factor

A method for isolating a desired protein which comprises: providing a host cell expressing the desired protein as an insoluble aggregate; culturing the host cell with an effective mount of Cu.sup.++ ; disrupting the host cell producing a lysate; incubating the insoluble fraction non-disulfide-bond reducing or non-copper competing chaotropic conditions to solubilize contaminants; separating the insoluble from the soluble fraction; and exposing the insoluble fraction to disulfide-bond reducing or copper competing chaotropic conditions to solubilize the desired protein.

Novel methods and compositions are provided for enhanced yield of heterologous proteins in fungi. The method and compositions involve employing fusion sequences involving a sequence encoding a heterologous product produced in relatively large amount as a stable polypeptide in the host fused to a second sequence in open reading frame with the prior sequence coding for a different heterologous polypeptide, where the two polypeptides are joined by a selectively cleavable linkage. In particular, a sequence coding for superoxide dismutase is joined to another polypeptide of interest at either terminus of the superoxide dismutase in a yeast expression vector under transcriptional control of an active promoter and the vector introduced into a yeast host and the host grown. High yields of the fusion product are obtained in this manner, where the fusion product can be selectively cleaved so as to produce both the superoxide dismutase and the other polypeptide in high yield. The S. cerevisiae strain 2150-2-3 (pYASI1) was deposited at the A.T.C.C. on Feb. 27, 1985 and given accession no. 20745. The S. cerevisiae strain AB110 (pYLUIGF2-14) was deposited at the A.T.C.C. on Mar. 19, 1986 and given accession no. 20796.

Superoxide dismutase fusion polypeptides for expression of mammalian

Methods and compositions are provided for efficient production of polypeptides having insulin activity. The proinsulin gene is joined to secretion and processing signals for expression and secretion in yeast. The product may be obtained in enhanced yield in the nutrient medium. Cell line pyinse was deposited at the A.T.C.C. on Apr. 6, 1983 and given Accession No. 20670.

Growing community of inventors

Oakland, CA, United States of America

Lawrence S Cousens